Featured Research

from universities, journals, and other organizations

Treatment For Mild Asthma Leads To Improved Lung Function

Date:
March 11, 2008
Source:
Woolcock Institute of Medical Research
Summary:
In patients with very mild or well-controlled asthma, regular treatment with low dose ICS leads to significantly better day--to-day lung function, new research shows.

A study by the Woolcock Institute of Medical Research in Sydney is the first to demonstrate that in patients with very mild or well-controlled asthma, regular treatment with low dose ICS leads to significantly better day--to-day lung function.

The study published in this month's edition of Primary Care Respiratory Journal was conducted over an 11 month period, and compared the effects of inhaled corticosteroids (ICS) and placebo on asthma control in mild asthmatics.

The results of the study raise questions about the current emphasis in asthma treatment which is based largely on controlling symptoms, and which does not advocate ICS treatment for patients with symptoms two days a week or less.

Results showed significant and clinically important treatment benefits on markers such as lung function, airway hyperresponsiveness and exhaled nitric oxide, which are all predictors of the risk of future adverse outcomes such as exacerbations.

Results indicated that a "ceiling" effect for lung function, often assumed to prevail in mild asthma, does not exist. Even patients whose lung function is over 90% of predicted normal value may have room to further improve their personal best with treatment.

The study also demonstrated subjects receiving placebo were nearly three times more likely to experience a mild exacerbation.

"In recent years the emphasis in asthma treatment has been on how well a patient's symptoms are is controlled," says Woolcock research leader Assoc. Prof. Helen Reddel.

"The patients in this study had asthma that was so mild, with symptoms once a week or less, that they themselves didn't see any benefit in regular preventer treatment," she said.

"However for those participants receiving ICS during the study, their lung function was better, they had less airway inflammation and less airway twitchiness. All of these things are predictors of reduction in risk of future adverse outcomes

"While we're not advocating that every patient with mild asthma should be on preventer medication, the study shows that when we are discussing the risks and benefits of treatment with these patients, we should talk about their risk of future exacerbations as well as whether they will notice any difference in their current symptoms".

"In the same way, for patients with high blood pressure, we talk about giving treatment to reduce their risk of stroke in the future rather than whether they will feel any different here and now."

Dr Reddel explains that while the study sample size was small, the measurement of airway twitchiness, airway inflammation and daily spirometry provided information about future risk that is often not possible in larger groups.


Story Source:

The above story is based on materials provided by Woolcock Institute of Medical Research. Note: Materials may be edited for content and length.


Cite This Page:

Woolcock Institute of Medical Research. "Treatment For Mild Asthma Leads To Improved Lung Function." ScienceDaily. ScienceDaily, 11 March 2008. <www.sciencedaily.com/releases/2008/03/080310103240.htm>.
Woolcock Institute of Medical Research. (2008, March 11). Treatment For Mild Asthma Leads To Improved Lung Function. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2008/03/080310103240.htm
Woolcock Institute of Medical Research. "Treatment For Mild Asthma Leads To Improved Lung Function." ScienceDaily. www.sciencedaily.com/releases/2008/03/080310103240.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins